A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer
Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Adrian L. Harris(University of Oxford), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Trivadi S. Ganesan(Churchill Hospital), S. Muthuramalingam(Churchill Hospital), Frances R. Balkwill(Queen Mary University of London), Kulwinder Kaur(Churchill Hospital), Susan Wilner(Churchill Hospital), Cheng Han(Churchill Hospital), Martin D. Foster(Churchill Hospital), Susan Hoare(Queen Mary University of London), Denis Talbot(Cancer Research UK)
Cited by 204
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k